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We retrospectively analysed the results of patients with advanced non-small-cell lung cancer treated with gefitinib to derive clinical
factors predictive of response and a favourable survival outcome. Patients were treated with gefitinib 250mg per day and re-
evaluated 4–8 weeks later with repeat CT scan and every 8 weeks thereafter to assess response and the duration of response.
Pathology review by a histopathologist was conducted, in particular to confirm a recently published result of bronchioloalveolar
carcinoma histology or its components as predictive of response to gefitinib. Logistic regression and Cox regression analytical
methods were applied to determine factors that could predict for response and improved overall survival. A total of 110 patients
were treated. The overall response rate was 32% partial responses (PRs). Only never-smoking status was predictive of response in
the logistic regression analysis, adjusted OR¼6.1, 95% CI¼1.7, 21.5. The presence of a PR and good performance status were
predictive of a favourable survival outcome from the Cox regression modelling. Responders had an adjusted HR of 3.0, 95%
CI¼1.5–5.8 compared to nonresponders, while patients with ECOG status 0–1 had an adjusted HR of 0.42, 95% CI¼0.25–0.72,
compared with patients with ECOG status 2–4. Bronchioloalveolar carcinoma or its components were distinctly absent on pathology
review. In conclusions, Never-smoking status is an important clinical predictor of a favourable response to gefitinib.
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The treatment of advanced non-small-cell lung cancer (NSCLC)
has seen significant advances over the past two decades. Platinum-
based regimens became established treatment due to the survival
advantage shown despite the modest response rates and short
duration of activity (Non-small Cell Lung Cancer Collaborative
Group, 1995). The second-generation agents such as vinorelbine,
gemcitabine, and taxanes have made further strides in this regard
(Bunn, 2002). However, further development of cytotoxics seems
to have hit a snag and it is the general feeling that this has peaked
and hence unlikely to cross the next hurdle.
Targeted therapy has now taken centre stage in cancer
therapeutics development. The success of trastuzumab (Herceptin)
and ST1571 (Gleevec) in the treatment of breast cancer and
gastrointestinal stromal tumours respectively heralded a new era in
solid tumour therapy (Slamon et al, 2001; Demetri et al, 2002).
Gefitinib (Iressa) became the first targeted form of treatment
available for treatment of NSCLC. The well-reported phase II
studies (IDEAL I and 2 trials) have shown encouraging responses
(8.8–19% response rates) even in patients who have been heavily
pretreated (Fukuoka et al, 2003; Kris et al, 2003).
Gefitinib first became available in Singapore in December 2000
through Astra-Zeneca’s Expanded Access Program and was
subsequently approved for use as salvage treatment for patients
with advanced NSCLC in the country in May 2003. We first
reported the clear superior activity of gefitinib among patients who
were never-smokers at the 39th American Society of Clinical
Oncology annual meeting. This report is a follow-up on an
expanded group of patients who were treated with gefitinib. The
purpose of this retrospective analysis was to assess the response to
gefitinib and to identify clinical parameters that may predict for
response to gefitinib. Being better able to select appropriate
patients for therapy would translate to better resource utilisation
especially since treatment using these novel agents is extremely
costly. In addition, this might form the basis for the identification
of a set of genetic parameters that can further predict gefitinib
sensitivity.
PATIENTS AND METHODS
Between January 2001 to October 2003, 110 patients with
metastatic NSCLC treated with gefitinib as monotherapy were
retrospectively reviewed. Among them, 33 patients were treated on
the Expanded Access Clinical Program. This cohort of 110 patients
came from a series of approximately 600 patients with NSCLC seen
in our department over the same time period. Most of patients
(92%) have failed at least one line of chemotherapy. Follow-up and
mortality information were available for all patients.
All patients had baseline CT scans, full blood count, liver and
renal biochemistries prior to treatment with gefitinib. CT scans
were performed 4–8 weeks after treatment to assess for response
according to World Health Organisation (WHO) standard criteria.
Stable disease (SD) and partial response (PR) were confirmed on
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srepeat CT scans not earlier than 4 weeks after the first evaluation
CT scan. Complete blood counts, renal biochemistries, and liver
biochemistries were repeated at 4–8 weeks intervals. Our centre’s
radiologists reviewed all CT evaluations. Other clinical information
such as age, sex, smoking history, histology, ECOG performance
status, and number of previous lines of chemotherapy prior to
gefitinib, were retrospectively reviewed and analysed for possible
association with response. Never-smoker was defined as one who
had never smoked at all prior to diagnosis of NSCLC. A smoker
was defined as one who was a current or ex-smoker.
We performed pathology review of the patients diagnosed in our
institutions. The thoracic histopathologist (KLC) was blinded to
the response outcome of the patients and was required to re-
classify the histology of the slides of the patients. In particular, he
was required to look specifically for bronchioloalveolar compo-
nents during the review, using the criteria described by Ebright
et al (2002) in their study.
Statistical methods
The following variables were included in a logistic regression
model to investigate their association with response – gender,
smoking history, ECOG performance status, age, number of lines
of prior chemotherapy, and histology. These factors, in addition to
response were investigated for their influence on survival using
Cox regression. All variables were entered simultaneously in both
models. Variables with P-value of less than 0.05 were considered
statistically significant. All analyses were performed using SPSS
version 10.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
The patient demographics are listed in Table 1. The median age of
patients when gefitinib was started was 55.8 years. In total, 53 and
60% of the patients were females and lifetime nonsmokers,
respectively. Majority of the patients (93%) were of Chinese
origin. Most of our patients had received at least two lines of
chemotherapy (71%) prior to starting gefitinib. The majority of the
patients were diagnosed with adenocarcinoma (71%). Only one
patient had bronchioloalveolar carcinoma. Pathology review did
not reveal any bronchioloalveolar carcinoma or such components
in those patients diagnosed in our institutions (Table 2). The slides
of 25 patients whose diagnoses were made elsewhere were not
available for review. The sole patient originally diagnosed to have
bronchioloalveolar carcinoma was reclassified as adenocarcinoma.
The overall observed PR rate was 32% (Table 3). There were no
complete responders (CR). Partial responses were, however,
experienced more commonly among patients who were of the
female gender (43 vs 19%), and lifetime never-smokers (47 vs 9%).
More partial responders were seen among female never-smokers
than their male counterpart (52 vs 33%), but this difference was
not statistically significant.
Using logistic regression, the following potential prognostic
factors were investigated for possible association with the response
outcome: gender, smoking history, age at diagnosis, number of
lines of prior chemotherapy, performance status using the ECOG
(Eastern Cooperative Oncology Group) scale, and histology. Only
smoking history turned out to be independently predictive of
response to gefitinib after adjusting for the other variables
(Table 4). Never-smokers had a 6.1 (95% CI, 1.7–21.5) higher
odds of response compared to smokers.
Overall survival was defined as the period from the date a
patient was started on gefitinib to the last follow-up date
(censored) or date of death. Figures 1 and 2 show the Kaplan–
Meier estimates of overall survival comparing responders (PR)
with nonresponders (SD/PD) and never-smokers with smokers,
respectively, not adjusting for any other variables. Responders had
a longer median overall survival compared to nonresponders (17.5
vs 7 months, HR¼3.0, 95% CI¼1.65–5.59). Never-smokers were
found to have a better overall survival than smokers (median
survival 13.6 vs 7.6 months, HR¼0.61, 9% CI¼0.38, 0.99).
The potential prognostic factors used in the logistic regression
earlier and the type of responses (PR vs SD/PD) were also
investigated in a Cox regression model to determine independent
predictive factors for improved survival outcome (Table 5). Of the
seven variables included, the presence of a PR and good ECOG
status were found to be predictive of improved survival. Patients
Table 1 Patient demographics
Characteristic Number %
Sex
Male 52 47
Female 58 53
Race
Chinese 102 93
Malay 5 5
Indian 3 3
Age when Iressa started (years)
Median (interquartile range) 55.8 (15.1)
Min, max 36.7, 92.1
Smoker
No 66 60.0
Yes 44 40.0
Histology
Adenocarcinoma 78 71
Squamous cell carcinoma 11 10
Large cell/undifferentiated 12 11
Bronchioloalveolar carcinoma 1 1
NSCLC, NOS 8 7
Performance status (ECOG)
0–1 79 72
2–4 31 28
No. of previous lines of chemotherapy
09 8
12 3 2 1
2 or more 78 71
Table 2 Pathology review vs original histology
Pathology review
Original histology Adeno- SCC UC LC BAC Not available Total
Adeno- 54 1 0 1 0 22 78
SCC 1 8 0 1 0 1 11
BAC 1 0 0 0 0 0 1
Others 3 0 1 1 0 0 5
PD 1 1 1 4 0 0 7
NOS 3 0 0 3 0 2 8
Total 63 10 2 10 0 25 110
Adeno-¼adenocarcinoma; SCC¼squamous cell carcinoma; BAC¼bronchioloal-
veolar carcinoma; PD¼poorly differentiated carcinoma; UC¼undifferentiated
carcinoma; NOS¼non-small-cell carcinoma, not otherwise specified. Not available:
slides not available for review.
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swith SD/PD had almost three times (95% CI 1.54–5.77) higher risk
of death compared to those with PR while those with good ECOG
status had 0.42 times lower risk of death (95% CI 0.25–0.72)
compared with the other group, adjusting for the other variables
found in the table. Smoking history was not found to be significant
in explaining survival, with an adjusted HR¼0.88 and 95%
CI¼0.48–1.63. Similar results were obtained when overall survival
was redefined as the period from date of diagnosis till the last
follow-up (censored) or date of death (Table 6).
Gefitinib was very well tolerated in our patients (Table 7). The
most common toxicity was rash, occurring in 38 (34.5%) patients.
However, the majority of patients had grade 1 and 2 toxicity. Other
common toxicities include conjunctivitis, diarrhoea, and elevation
of the serum transminases.
DISCUSSION
Gefitinib is the first targeted therapy proven to work and approved
for use as salvage treatment in advanced NSCLC. The response
rates in the salvage setting as obtained from IDEAL 1 and 2 studies
are comparable to that of docetaxel, which is currently the
standard of care for second-line use (Shepherd et al, 2000;
Fukuoka et al, 2003; Kris et al, 2003). However, its superior toxicity
profile and convenient oral dosing form stand out as definite
advantages when compared to cytotoxics. Its targeted and selective
inhibition of HER1/EGFR tyrosine kinase and hence the down-
stream pathway(s) driving and maintaining carcinogenesis ac-
counts for its low toxicity and for its non-cross resistance with
cytotoxics. Our study and others have shown that previous
exposure to chemotherapy did not have an effect on subsequent
response to gefitinib (Haringhuizen et al, 2004; Miller et al, 2004b).
Table 3 Response rates by smoking status and gender
Status Partial Stable Progressive ORR (%)
All patients (n¼110) 35 15 60 32
Nonsmoker (n¼66) 31 10 25 47
Smoker (n¼44) 4 5 35 9
Female nonsmoker (n¼48) 25 8 15 52
Male nonsmoker (n¼18) 6 2 10 33
Female smoker (n¼10) 0 2 8 0
Male smoker (n¼34) 4 3 27 12
Chinese (102) 34 13 55 33
Malay (5) 1 2 2 25
Indian 0 0 3 0
ORR¼overall response rate.
Table 4 Logistic regression analysis of response to Iressa
Coefficient
(s.e.)
Odds
ratio
95%
confidence
interval P-value
Gender 0.42
Female (n¼58) 0.42 (0.52) 1.53 0.55, 4.24
Male (n¼52) — 1 —
Smoker 0.005
No (n¼66) 1.80 (0.64) 6.08 1.72, 21.43
Yes (n¼44) — 1 —
Age in years 0.25
o60 (n¼65)  0.57 (0.49) 0.57 0.22, 1.49
X60 (n¼45) — 1 —
No. of lines of
chemotherapy
0.62
0–1 (n¼32)  0.26 (0.52) 0.77 0.28, 2.15
X2( n¼78) — 1 —
ECOG status 0.53
0–1 (n¼79) 0.34 (0.54) 1.40 0.48, 4.07
2–4 (n¼31) — 1 —
Squamous cell
histology
0.99
Yes (n¼11)  19.55
(11737.8)
o0.001 0, N
No (n¼99) — 1 —
Constant  2.01 (0.75) 0.13 — 0.007
s.e.¼standard error of regression coefficient.
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Figure 1 Kaplan–Meier estimates of overall survival time comparing
responders (CR/PR) and nonresponders (SD/PD).
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Figure 2 Kaplan–Meier estimates of overall survival time comparing
never-smokers and smokers.
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sIts specificity for a particular target also implies the possibility of
using a biomarker to predict for response, similar to HER2 status
predicting for response to trastuzumab in breast cancer (Yu and
Hung, 2000). Despite the obvious target of gefitinib, expression of
EGFR is not predictive for response to gefitinib (Bailey et al, 2003).
Until recently, no biomarkers or clinical features were found to be
predictive for response to gefitinib. For this reason, the INTACT
investigators were unselective in the patient populations for their
studies and this failure to adequately select for appropriate
patients probably led to a negative outcome in contradistinction
to the trastuzumab study in metastatic breast cancer (Giaccone
et al, 2004; Herbst et al, 2004).
Our initial experience with gefitinib in patients with advanced
NSCLC after failing multiple lines of cytotoxics intrigued us in that
we noticed that the responders were mainly those who were never-
smokers. It is of interest that others also had similar experiences
(Haringhuizen et al, 2004; Miller et al, 2004b). It is known that
there are significant differences in the mutational frequencies and
spectra in lung cancers between smokers and nonsmokers. For
instance, p53 and K-ras mutations were detected more frequently
in smokers with lung cancer (Ahrendt et al, 2000; Gealy et al,
2001). That would imply that the predominant pathways driving
and/or maintaining the carcinogenic process might be different
between these two groups of patients. Sanchez-Cespedes et al
(2001) and Wong et al (2002) used microsatellite analysis to
characterise and to determine the frequency of loss of hetero-
zygosity/allelic gains in adenocarcinoma of the lung from smokers/
ex-smokers and nonsmokers and found distinct differences
between the two groups. Although the results of both studies were
somewhat discrepant, it is clear that the genetic makeup of
adenocarcinoma from smokers and nonsmokers is different. It is
conceivable that different genetic pathways are involved in
carcinogenesis between these two groups from these studies.
We looked for possible differences in outcome between smokers
and nonsmokers in patients with advanced NSCLC treated with
platinum-based chemotherapy in our previous study (Toh et al,
2004). In that study that included 317 patients (115 patients were
nonsmokers), no differences were observed in terms of response to
cytotoxics and survival outcome between smokers and nonsmo-
kers despite distinct differences in age at diagnosis, and histology,
and gender distribution. Given that cytotoxics kill cancer cells in a
nonselective manner in that they do not target specific molecular
pathway(s), it can be difficult to appreciate the impact of any
mutational differences between these two groups of patients with
the use of chemotherapy. Gefitinib, a more targeted form of
Table 5 Cox regression analysis of potential factors predictive of overall
survival (defined as period from date Iressa started till last follow-up date or
death)
Coefficient
(s.e.)
Hazards
ratio
95%
confidence
interval P-value
Gender
Female (n¼58)  0.04 (0.29) 0.96 0.54, 1.70 0.88
Male (n¼52) — 1 —
Smoker
No (n¼66)  0.12 (0.31) 0.88 0.48, 1.63 0.69
Yes (n¼44) — 1 —
Age in years
o60 (n¼65) 0.14 (0.30) 1.15 0.64, 2.08 0.63
X60 (n¼45) — 1 —
No. of lines of
chemotherapy
0–1 (n¼32)  0.29 (0.31) 0.75 0.41, 1.38 0.36
X2( n¼78) — 1 —
ECOG status
0–1 (n¼79)  0.86 (0.27) 0.42 0.25, 0.72 0.002
2–4 (n¼31) — 1 —
Squamous cell
histology
No (n¼99)  0.27 (0.45) 0.77 0.32, 1.84 0.55
Yes (n¼11) — 1 —
Response
SD/PD (n¼75) 1.09 (0.34) 2.98 1.54, 5.77 0.001
CR/PR (n¼35) — 1 —
Table 6 Cox regression analysis of potential factors predictive of overall
survival (defined as period from date of diagnosis till last follow-up date or
death)
Coefficient
(s.e.)
Hazards
ratio
95%
confidence
interval P-value
Gender
Female (n¼58)  0.04 (0.29) 0.96 0.54, 1.70 0.88
Male (n¼52) — 1 —
Smoker
No (n¼66)  0.12 (0.31) 0.88 0.48, 1.63 0.69
Yes (n¼44) — 1 —
Age in years
o60 (n¼65) 0.14 (0.30) 1.15 0.64, 2.08 0.63
X60 (n¼45) — 1 —
No. of lines of
chemotherapy
0–1 (n¼32)  0.29 (0.31) 0.75 0.41, 1.38 0.36
X2( n¼78) — 1 —
ECOG status
0–1 (n¼79)  0.86 (0.27) 0.42 0.25, 0.72 0.002
2–4 (n¼31) — 1 —
Squamous cell
histology
No (n¼99)  0.27 (0.45) 0.77 0.32, 1.84 0.55
Yes (n¼11) — 1 —
Response
SD/PD (n¼75) 1.09 (0.34) 2.98 1.54, 5.77 0.001
CR/PR (n¼35) — 1 —
Table 7 Common toxicities
Toxicity profile Grade 1 (%) Grade 2 (%) Grade 3 (%) Grade 4 (%)
Rash 29 (26) 5 (5) 3 (3) 1 (1)
Eyes 8 (7) 0 0 0
Diarrhoea 10 (9) 0 0 0
Asthenia 1 (1) 2 (2) 0 1 (1)
Leucopenia 1 (1) 1 (1) 0 0
Thrombocytopenia 0 0 1 (1) 0
Anaemia 17 (16) 5 (5) 1 (1) 0
Bilirubinemia 4 (4) 1 (1) 0 0
Transaminitis 13 (12) 3 (3) 1 (1) 5 (5)
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streatment that inhibit the predominant pathway(s) that initiate
and maintain the carcinogenic process may make this biological
difference between tobacco-induced and nontobacco induced lung
cancer more manifest. This is in line with the observations made in
this and other studies as well (Yu and Hung, 2000; Haringhuizen
et al, 2004).
The recent discovery of somatic activating mutations in the
tyrosine kinase domain of the EGFR gene in the tumour brings
new hope of improved ability to predict response to gefitinib
(Lynch et al, 2004; Paez et al, 2004). These two studies found that
these mutations predicted well for gefitinib response. However,
both studies included small numbers of patients treated with
gefitinib. In addition, Paez et al found that these mutations were
present more frequently in adenocarcinomas, female gender, and
patients from Japan in a cohort of 119 patients who were not
treated with gefitinib. It was not established in this study whether
the mutations correlated with nonsmoking status as well although
Lynch et al’s (2004) study does suggest indirectly that a correlation
with nonsmoking status was found. Lynch et al also sequenced the
entire coding region of the EGFR gene in tumours from 25 patients
with NSCLC not treated with gefitinib, including 15 patients with
bronchioloalveolar carcinoma, and found these mutations in two
patients, both of whom had bronchioloalveolar carcinoma. These
findings are certainly intriguing and will need confirmation in a
larger study population. Further studies will need to be done to
confirm if Asian and Caucasian patients differ significantly in this
aspect. If the latter proves to be so, it implies that gefitinib would
benefit Asian patients more than Caucasian patients.
Miller et al (2004b) reported that the presence of bronchio-
loalveolar component as an independent predictor of gefitinib
responsiveness. However, this finding was not observed in our
study. Only nonsmoking status was predictive of response to
gefitinib in our cohort. Similarly, in a recent report from Korea
involving 90 patients with NSCLC treated with gefitinib, histology
was not found to be an independent predictor for response to
gefitinib (Han et al, 2005). Of importance, the frequency of EGFR
mutation in patients with bronchioalveolar carcinoma was similar
to that seen in patients with non-BAC adenocarcinomas (Han et al,
2005). Thus, it remains to be established if bronchioloalveolar
histology is associated with a distinct mutational spectrum that is
different from the other histological entities. Moreover, the
classification of variants of bronchioloalveolar histology suffers
from interobserver differences and reproducibility. This coupled
with the rarity of this histological type and its subtypes further
reduced its usefulness as a predictive factor for response to
gefitinib.
Until a confirmed biomarker for response to gefitinib is
routinely and readily available, an economical and simple way to
select for appropriate patients for this expensive form of treatment
is the smoking status. Based on the relatively higher incidence of
never-smokers diagnosed with lung cancer especially among
women in Asia, it does suggest that a higher proportion of
patients in this part of the world may benefit from treatment with
gefitinib (MacLennan et al, 1977; Koo et al, 1985; Gao et al, 1987;
Han et al, 1990). Our previous study revealed that 36% of patients
referred to our department were never-smokers (Toh et al, 2004).
Despite the negative results from the INTACT studies, it is still
worthwhile exploring the use of chemotherapy with gefitinib in
never-smoking patients with advanced NSCLC. The TRIBUTE
study, which compared erlotinib (Tarceva) with placebo in
patients with advanced NSCLC receiving paclitaxel and carboplatin
as first-line therapy was reported at the 2004 Annual Meeting of
the American Society of Clinical Oncologist (Miller et al, 2004a).
The design and the final results of this study were similar to the
INTACT studies. However, a predetermined analysis of the subset
of patients who never smoked showed a significantly improved
median survival in those randomised to received erlotinib (23 vs 10
months; HR 0.49, CI 0.28–0.85).
It is important that there should be continuing efforts at genetic
profiling of lung cancer patients in Asia to allow correlation with
treatment response especially to targeted agents. Such a prospec-
tive study is ongoing in this centre.
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